Annual Report 2025

Change report

Consolidated statement of income

Consolidated statement of income

€ in millions

 

Note

 

2025

 

2024 restated1

 

2024 previous

Revenue

 

4

 

22,873

 

21,954

 

21,833

Costs of revenue

 

 

 

-17,180

 

-16,317

 

-16,455

Gross profit

 

 

 

5,693

 

5,637

 

5,378

Selling expenses

 

 

 

-615

 

-679

 

-697

General and administrative expenses

 

8

 

-2,268

 

-2,209

 

-2,222

Other operating income

 

9

 

411

 

290

 

293

Other operating expenses

 

9

 

-278

 

-325

 

-329

Research and development expenses

 

7

 

-633

 

-641

 

-641

Operating income (EBIT)

 

 

 

2,310

 

2,073

 

1,782

Income from investments accounted for using the equity method

 

22

 

198

 

38

 

38

Interest income

 

10

 

116

 

123

 

115

Interest expenses

 

10

 

-445

 

-552

 

-547

Other financial result

 

29

 

9

 

 

Income before income taxes

 

 

 

2,188

 

1,682

 

1,388

Income taxes

 

11

 

-582

 

-530

 

-521

Net income from continuing operations

 

 

 

1,606

 

1,152

 

867

Noncontrolling interests in continuing operations

 

12

 

70

 

24

 

-34

Net income from continuing operations attributable to shareholders of Fresenius SE & Co. KGaA

 

 

 

1,536

 

1,128

 

901

 

 

 

 

 

 

 

 

 

Net income from discontinued operations

 

 

 

-272

 

-856

 

-571

Noncontrolling interests from discontinued operations

 

 

 

0

 

-199

 

-141

Net income from discontinued operations attributable to shareholders of Fresenius SE & Co. KGaA

 

 

 

-272

 

-657

 

-430

 

 

 

 

 

 

 

 

 

Net income

 

 

 

1,334

 

296

 

296

Noncontrolling interests in net income

 

 

 

70

 

-175

 

-175

Net income attributable to shareholders of Fresenius SE & Co. KGaA

 

 

 

1,264

 

471

 

471

 

 

 

 

 

 

 

 

 

Earnings per share in € (basic and diluted)

 

14

 

2.24

 

0.84

 

0.84

thereof based on net income from continuing operations

 

 

 

2.72

 

2.00

 

1.60

thereof based on net income from discontinued operations

 

 

 

-0.48

 

-1.16

 

-0.76

1

Prior-year figures have been adjusted due to the gradual exit from Fresenius Vamed (see note 1. III. c, Classifications).

The following notes are an integral part of the consolidated financial statements.